GZR102

GZR102 is a **class 1 innovative biological product** developed for the treatment of type 2 diabetes and overweight. It is a **dual-action therapy** that acts as both a **glucagon-like peptide 1 receptor (GLP-1R) agonist** and an **insulin receptor (INSR) agonist**. This investigational therapy is designed to improve glycemic control by combining the benefits of GLP-1R agonists (which enhance insulin secretion and suppress glucagon) and basal insulin action through INSR stimulation. GZR102 is formulated for **once-weekly injection** and aims to provide therapeutic benefits for metabolic conditions such as type 2 diabetes and overweight. It is currently under clinical development and has entered Phase 1 trials[1][3][4][5][7][9].